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http://www.biomedcentral.com/1471-2261/14/67RESEARCH ARTICLE Open AccessPlasma NT pro-BNP, hs-CRP and big-ET levels at
admission as prognostic markers of survival in
hospitalized patients with dilated cardiomyopathy:
a single-center cohort study
Xiaoping Li1,2†, Chengzhi Chen1,3†, Feng Gan1,4†, Yang Wang1, Ligang Ding1 and Wei Hua1*Abstract
Background: Circulating N-terminal pro-B-type natriuretic peptide (NT pro-BNP), high- sensitivity C-reactive protein
(hs-CRP) and big endothelin (big-ET) have been shown to be increased in heart failure and to contribute to both
hemodynamic deterioration and cardiovascular remodeling. Here, we examined the prognostic value of the three
neurohormones at admission in a population of hospitalized patients with dilated cardiomyopathy (DCM).
Methods and results: This cohort study was undertaken in 622 hospitalized patients with DCM in Fuwai Hospital
from January 2005 to September 2011 (female 26.5%, 51.4 ± 14.6 years old). Standard demographics, echocardiography
and routine blood samples were obtained shortly after admission. NT pro-BNP, hs-CRP and big-ET were measured, and
their concentrations in relation to all-cause mortality were assessed through a mean follow-up of 2.6 ± 1.6 years.
Kaplan-Meier curves showed that the all-cause mortality rates were higher in patients with NT pro-BNP > 2247
pmol/L compared to patients with NT pro-BNP < 2247 pmol/L (11.9% vs 34.8%, log-rank χ2 = 35.588, P < 0.001),
in patients with hs-CRP > 3.90 mg/L compared to patients with hs-CRP < 3.90 mg/L (12.8% vs 33.6%, log-rank χ2 = 39.662,
P < 0.001) and in patients with big-ET > 0.95 pmol/L compared to patients with big-ET <0.95 pmol/L (12.5% vs 31.0%,
log-rank χ2 = 17.890, P < 0.001). High circulating concentrations of NT pro-BNP (HR 2.217, 95% CI 1.015-4.846, P = 0.046)
and hs-CRP (HR 1.922, 95% CI 1.236-2.988, P = 0.004), but not big-ET, in addition to left atrial diameter and fasting blood
glucose, were independent predictors of the outcome defined as all-cause mortality.
Conclusions: In a large population of patients with DCM, the circulating concentrations of NT pro-BNP and hs-CRP,
but not big-ET, were independent markers of all-cause mortality.
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B-type natriuretic peptide (BNP) is a cardiac peptide
that is secreted from membrane granules in the cardiac
ventricles as a response to ventricular volume expan-
sion and pressure overload [1,2]. In the family of natri-
uretic peptides, N-terminal pro-B-type natriuretic
peptide (NT pro-BNP) is the best predictor of clinical* Correspondence: drhua@yahoo.cn
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unless otherwise stated.outcome because it is larger and has a longer half-life
than BNP, making its measurement easier [3]. BNP and
NT pro- BNP have become valuable biomarkers for
confirming the diagnosis of heart failure (HF) [4,5] and
have been predictive of outcomes among ambulatory
and hospitalized HF patients [6-8].
C-reactive protein (CRP) is a nonspecific biochemical
marker of inflammation. Studies have shown a link be-
tween CRP and various cardiovascular diseases such as
atherosclerosis [9-11], hypertension [12], and chronic
HF [13-15]. Increased CRP levels have been recognized
as an independent predictor of all-cause and cardiovas-
cular mortality in cardiovascular disease and in thehis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.biomedcentral.com/1471-2261/14/67general population [9-15]. Although the serum concen-
trations of CRP are elevated in patients with heart fail-
ure, especially those with severe acute HF [13-16],
clinical data regarding the prognostic value of CRP in
patients with chronic heart failure have been sparse
and inconsistent [13,16,17]. Standard clinical assays for
CRP lack sensitivity, but high-sensitivity CRP (hs-CRP)
assays are now available and provide a better way to
determine the predictive value for the prognosis of pa-
tients with CHF.
Elevated plasma concentrations of endothelin (ET)
and of its precursor (big-ET) have been measured in
patients with chronic HF [18-20] and have also been
significantly associated with clinical outcomes in HF
patients [21-24]. As circulating ET has a very short
half-life, it is not easy to detect its circulating levels;
however, circulating levels of big-ET have a longer
half-life and are stable and easy to detect.
Although there have been clinical data showing that
NT pro-BNP, hs-CRP and big-ET were elevated and
were prognostic markers of survival in patients with
chronic HF [6-8,13,16,17,21-24], there have been limited
data on the prognostic values of these three biomarkers
in DCM patients. Therefore, in the present study, we
sought to investigate the significance of NT pro-BNP,
hs-CRP and big-ET levels in hospitalized patients with
DCM and to test the hypothesis that the three bio-
markers could be prognostic markers of all-cause mor-
tality in these patients.
Methods
Patients and follow-up
A retrospective, observational cohort study of 622 DCM
patients from 2005 January to 2011 September was con-
ducted. The patients were admitted for decompensated
heart failure and the physical signs of HF at Fuwai
Hospital, and all patients were hospitalized during 2005
January to 2011 September. DCM was defined as systolic
dysfunction (left ventricular [LV] ejection fraction <50%)
with LV dilation [defined as left ventricular end-diastolic
diameter (LVEDd) > 55 mm for males or LVEDd > 50 mm
for females] in the absence of an apparent secondary cause
of cardiomyopathy [25] (e.g., ischaemic heart disease based
on coronary angiography, overt hyper- and hypothyroidism
thyroid disease, alcohol-induced cardiomyopathy, congeni-
tal heart disease, left ventricle noncompaction, chronic an-
aemia (hemoglobin <60 g/L), peripartum cardiomyopathy,
heart valvular disease, combined with systemic immune
disease or blood pressure more than 160/100 mmHg at ad-
mission). The primary end point of the study was all-cause
mortality, which was assessed for all patients through their
medical records (patients’ hospital records, periodically
examining the patients in the outpatient clinic) and medical
follow-up calls with trained personnel from admission untilJuly 31, 2012. The follow-up rate was 92.7% with a mean
follow-up duration of 2.6 ± 1.6 years. The study protocol
was approved by the Ethics Commission of Fuwai Hospital.Measurement of big-ET, hs-CRP and NT pro-BNP
Plasma NT pro-BNP was measured in the day next to
the admission using a commercial enzyme immuno-
assay (Biomedica, Vienna, Austria). The inter-assay
coefficient of variation was 8% and the intra-assay co-
efficient of variation was 6%, with a detection limit of
171 pmol/L. Serum hs-CRP was measured using the
Particle Enhanced Immunoturbidimetric Assay (Orion
Diagnostica, Finland), where the detection limit was
less than 0.25 mg/L, the inter-assay coefficient of vari-
ation was ≤8.71% and the intra-assay coefficient of
variation was ≤11.9. Plasma big-ET was measured
without prior extraction with the use of a commercial
enzyme immunoassay (Biomedica, Vienna, Austria).
Cross-reactivity was less than 1% for ET-1, ET-2, and
ET-3. The inter-assay and intra-assay coefficients of
variation were less than 5% and the detection limit was
0.02 pmol/L.Statistical analysis
Continuous variables are expressed as the mean ± SD or as
medians and interquartile ranges. Baseline characteristics
between the categories of NT pro-BNP (below/above 2247
pmol/L), hs-CRP (below/above 3.90 mg/L) and big-ET
(below/above 0.95 pmol/L) were compared using the
chi-square test for categorical variables; for continuous
variables, comparisons were performed using an inde-
pendent sample t-test.
Receiver-operating characteristic (ROC) analysis was
performed to determine the optimal prognostic con-
centrations of big-ET, hs-CRP and NT pro-BNP for the
study outcomes. Kaplan-Meier survival curves were
compared using the log-rank test. Cox proportional
hazard models were used to estimate the univariate
and multivariable hazards of all-cause mortality associ-
ated with each individual parameter. Based on clinical
and statistical significance in the univariate Cox ana-
lysis, the following covariates were used in multivari-
able models: age, gender, history of diabetes mellitus
and atrial fibrillation (AF), New York Heart Associ-
ation (NYHA) functional class, disease duration, blood
pressure, QRS duration, left ventricle (LV) and left
atrium (LA) diameters, LVEF, fasting blood glucose,
serum creatinine levels, NT pro-BNP, hs-CRP and big-
ET. SPSS (Statistical Package for the Social Sciences)
version 16.0 software (SPSS, Chicago, Illinois) was used
for all statistical analyses. All tests were 2-sided and
a P value < 0.05 was used to determine statistical
significance.
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Value of NT pro-BNP, hs-CRP and big-ET in predicting all-
cause mortality
To evaluate the value of NT pro-BNP, hs-CRP and big-
ET in predicting all-cause mortality in 622 patients with
DCM, the receiver operating characteristic (ROC) curve
was drawn. The optimal cutoff concentrations of NT
pro-BNP, hs-CRP and big-ET for the prediction of the
outcome of interest were determined using ROC ana-
lysis. For big-ET, the optimal cutoff of 0.95 pmol/L cor-
responded to a specificity of 0.597 and a sensitivity of
0.679 (area under the curve (AUC): 0.665 ± 0.028 [SD],
P < 0.0001). For hs-CRP, the optimal cutoff of 3.90 mg/L
corresponded to a specificity of 0.666 and a sensitivity of
0.634 (AUC 0.680 ± 0.026, P < 0 .0001). For NT pro-BNP,
the optimal cutoff of 2247 pmol/L corresponded to a
specificity of 0.712 and a sensitivity of 0.616 (AUC 0.703 ±
0.028, P < 0 .0001).
Characteristics of the study population
The study consisted of 622 patients with DCM. The
mean age of the enrolled patients was 51.4 ± 14.6 years,
and 26.5% were female. Compared to patients with an
NT pro-BNP <2247 pmol/L, patients with an NT pro-
BNP >2247 pmol/L were more likely to be in NYHA
classes III and IV, have larger LV diameters, more de-
pressed LV ejection fractions (LVEF) and more dilated
RV and LA diameters; these patients were also more
likely to be taking aspirin and beta-blockers but were
less likely to be taking digoxin. Patients with higher NT
pro-BNP also had significantly higher levels of blood
urea nitrogen and creatinine, higher heart rates, lower
blood pressure and longer QRS duration. Compared to
patients with hs-CRP < 3.90 mg/L, patients with hs-CRP
> 3.90 mg/L were more frequently in NYHA classes III
and IV and had more a depressed LV ejection fraction
and more dilated RV and LA diameter. Additionally,
these patients were more likely to be on digoxin and less
likely to be taking ACEIs and beta-blockers, and had sig-
nificantly higher levels of NT pro-BNP, creatinine, and
higher SBP and heart rates. Compared to patients with a
concentration of big-ET-1 < 0.95 pmol/L, patients with a
concentration of big-ET-1 > 0.95 pmol/L were more
likely to have atrial fibrillation, to be in NYHA classes
III and IV, to have more depressed LV ejection fractions
and more dilated LV, right ventricle (RV) and left atrial
(LA) diameters, more likely to be taking diuretics and
digoxin, and had significantly higher levels of NT pro-
BNP and creatinine (Table 1).
Relation between NT pro-BNP, hs-CRP, big-ET levels and
all-cause mortality
Among the 622 patients studied, 131 (21.1%) died over a
mean follow-up of 2.6 ± 1.6 years. At the mean follow-up of 2.6 years, Kaplan-Meier curves demonstrated that
all-cause mortality was higher in patients with NT pro-
BNP > 2247 pmol/L compared to the patients with NT
pro-BNP < 2247 pmol/L (11.9% vs 34.8%, log-rank χ2 =
35.588, P < 0.001), that all-cause mortality rates were
higher in patients with hs-CRP > 3.90 mg/L compared to
the patients with hs-CRP < 3.90 mg/L (12.8% vs 33.6%,
log-rank χ2 = 39.662, P < 0.001) and that all-cause mor-
tality rates were higher in patients with big-ET > 0.95
pmol/L ompared to the patients with big-ET <0.95
pmol/L (12.5% vs 31.0%, log-rank χ2 = 17.890, P < 0.001)
(Figure 1).
Cox proportional hazard models
Univariate analyses indicated that age, history of essen-
tial hypertension and AF, NYHA functional classes, sys-
tolic blood pressure, QRS duration, LV and LA
diameters, LVEF, circulating creatinine levels, NT pro-
BNP, fasting blood glucose, serum creatinine levels, big-
ET and hs-CRP were all predictors of all-cause mortality
in DCM patients. After adjusting for age, gender, history
of DM and AF, disease duration, creatinine levels, LV
diameter and LVEF value, using either forward or back-
ward selection, LA diameter, fasting blood glucose, hs-
CRP > 3.90 mg/L and NT pro-BNP > 2247 pmol/L were
the variables that remained in the model as the inde-
pendent predictors of all-cause mortality. However, un-
like hs-CRP > 3.90 mg/L and NT pro-BNP > 2247 pmol/L,
big-ET > 0.95 pmol/L was not a predictor of death in the
multivariate Cox analysis (Table 2).
Discussion
In this study, we investigated the associations between
circulating levels of NT pro-BNP, hs-CRP and big-ET
and all-cause mortality in patients with DCM. Our
major new finding suggests that at admission, plasma
NT pro-BNP and hs-CRP, but not big-ET, were strong
predictors of all-cause mortality in DCM patients, and
this association was independent of traditional risk fac-
tors for adverse outcomes in HF and DCM such as age,
LV diameter, NYHA functional class, and the LVEF.
Concentrations of NT pro-BNP are related to LV fill-
ing pressures and wall stress [26]. B-type natriuretic pep-
tide levels have been shown to be elevated in patients
with symptomatic LV dysfunction and correlate to LV
filling pressure, NYHA classification and prognosis
[27-29]. NT pro-BNP levels increase during left ven-
tricular dysfunction and acute myocardial infarction, and
serve to counteract mechanisms of heart failure through
diuresis, natriuresis and antihypertensive effects [4-8].
Various timing of the natriuretic peptide measurements
among hospitalized HF patients indicated that NT pro-
BNP levels were associated with outcomes including
mortality and morbidity [30-33]. There is also evidence
Table 1 Patient characteristics categorized by plasma NT-pro-BNP levels1
All of the patients
(n = 560)
NTpro-BNP < 2247
pmol/mL (n = 362)
NT pro-BNP > 2247
pmol/mL (n = 198)
P value
Age (years) 51.0 ± 14.2 51.1 ± 13.4 51.0 ± 15.8 0.958
Female sex, n (%) 146 (26.1) 98 (27.1) 48 (24.2) 0.466
History
Course 3 (0.5-7) 2 (0.35-7) 3 (0.6375-6) 0.909
Diabetes mellitus 83 (14.8) 58 (16.0) 25 (12.6) 0.280
Atrial fibrillation, n (%) 121 (21.6) 76 (21.0) 45 (22.7) 0.634
Smoker, n (%)2 265 (47.3) 169 (46.8) 96 (48.9) 0.625
Drinker, n (%)2 170 (30.4) 119 (32.9) 51 (26.0) 0.089
NYHA class III and IV, n (%)3 425 (75.9) 247 (68.2) 178 (89.9) <0.001
Admission vital signs
SBP (mm Hg)3 113.3 ± 17.7 116.0 ± 17.6 108.3 ± 16.7 <0.001
DBP (mm Hg)3 72.3 ± 12.6 73.3 ± 12.5 70.5 ± 12.5 0.012
Heart rate, beat/min 80.8 ± 17.1 79.1 ± 16.0 84.0 ± 18.6 0.002
Laboratory values at admission2
Glucose (mmol/L) 5.53 ± 1.70 5.49 ± 1.43 5.62 ± 2.10 0.386
TG (mmol/L)3 1.58 ± 0.89 1.74 ± 0.99 1.27 ± 0.57 <0.001
TC (mmol/L)3 4.59 ± 1.11 4.78 ± 1.08 4.22 ± 1.07 <0.001
Creatinine (μmol/L) 91.9 ± 34.2 87.5 ± 26.5 100.0 ± 44.0 <0.001
BUN (μmol/L)3 8.02 ± 4.07 7.68 ± 3.90 8.63 ± 4.33 0.010
NT Pro-BNP (pmol/mL)3 1652.85 (837.375-2907.2) 1051.45 (700.7-1613.675) 3425.25 (2787.975-4713.125) <0.001
Electrocardiogram data4
QRS duration (ms) 119.6 ± 30.1 117.6 ± 28.3 123.4 ± 33.0 0.029
QT (ms) 408.0 ± 50.7 410.9 ± 49.6 402.6 ± 52.4 0.067
Echocardiography data4
LV (mm)3 68.5 ± 9.5 67.1 ± 8.7 71.1 ± 10.3 <0.001
LVEF (mm)3 31.1 ± 8.4 32.6 ± 8.4 28.1 ± 7.6 <0.001
RV (mm) 24.2 ± 5.4 23.1 ± 4.9 26.2 ± 5.8 <0.001
LA (mm)3 44.5 ± 7.8 42.9 ± 7.7 47.4 ± 7.2 <0.001
Medicine at admission2
Diuretics, n (%) 529 (94.5) 339 (94.4) 190 (97.4) 0.103
ACEI/ARB, n (%)3 473 (84.5) 315 (87.5) 158 (81.9) 0.073
Beta-blockers, n (%) 509 (90.9) 340 (94.4) 169 (87.1) 0.003
Digoxin, n (%) 449 (80.2) 280 (78.0) 169 (86.7) 0.013
Aspirin/anticoagulation n (%) 353 (63.0) 243 (67.5) 110 (56.4) 0.010
Spironolactone, n (%) 514 (91.8) 331 (91.9) 183 (93.8) 0.414
Note:
1Data are expressed as the mean ± SD, median (interquartile range) or percentage; P values are from an independent-samples t-test.
2Smoker was defined using standard questions about current smoking and lifetime smoking at least 100 cigarettes; drinkers who reported drinking 1 drink a day
on average on days that they consumed alcohol during the previous year.
3Abbreviations: NYHA New York Heart Association, SBP systolic blood pressure DBP diastolic blood pressure, BUN blood urea nitrogen TG triglyceride, TC total cholesterol,
NT pro-BNP N-terminal fragment pro-brain natriuretic peptide, LV left ventricle, RV right ventricle, LA left atrium, LVEF left ventricular ejection fraction, ACEI angiotensin-
converting enzyme inhibitor, ARB angiotensin receptor blocker.
4Seven patients lacked echocardiography data, 9 patients lacked electrocardiogram data, 4 patient lacked fasting blood glucose, 1 patient lacked creatinine, 2
patients lacked BUN levels, 5 patients lacked triglyceride, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol levels and
6 patients lacked medicines at admission.
The bold data indicated that P<0.05.
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Figure 1 Kaplan-Meier survival curves for patients with dilated
cardiomyopathy: the upper panel: patients with NT pro-BNP<
2247 pmol/L and NT pro-BNP> 2247 pmol/L with DCM (log-rank
χ2 = 35.588, P < 0.001). The middle panel: patients with hs-CRP <
3.90 mg/L and hs-CRP > 3.9 mg/L with DCM (log-rank χ2 = 39.622,
P < 0.001). The lower panel: patients with big-ET < 0.95 pmol/L and
big-ET > 0.95 pmol/L (log-rank χ2 = 17.890, P < 0.001).
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morbidity related to chronic HF; a BNP-guided therapeutic
strategy was superior to a clinically guided approach in
NYHA functional class II to III patients who were consid-
ered optimally treated by chronic HF specialists [34,35].
There were limited data on the prognostic value of BNP orNT pro-BNP in DCM patients; the BNP or NT pro-BNP
levels increased and were associated with cardiac events or
mortality [36,37]. In the present study, NT pro-BNP was
increased in patients in NYHA classes III and IV with de-
pressed LVEF and larger dilated RV and LA diameters, and
NT pro-BNP was one of the independent predictors of all-
cause mortality in DCM patients.
Many studies have suggested that the role of CRP in car-
diac disease is as an acute phase-reactant protein. CRP is
mainly produced in the liver in response to interleukin-6
and plays many pathophysiological roles in the inflamma-
tory process. Elevated levels of CRP have been observed in
patients with HF [13-15], and activation of the immune
response may play a role in heart failure through modi-
fications in the renin-angiotensin-aldosterone and sym-
pathetic systems [38,39]. There is evidence that chronic
activation of the immune system such as monocyte-
macrophage and lymphocyte activation exists in HF [38,39].
CRP may not only be a marker of chronic systemic inflam-
mation but also may be directly involved in CHF. CRP can
cause myocardial cell apoptosis, and thus ventricular damage
or dysfunction [40]. In the present study, hs-CRP was in-
creased in patients in NYHA classes III and IV with de-
pressed LVEF, more dilated right ventricular and left atrial
diameters. Patients with an hs-CRP >3.90 pmol/L also had
higher all-cause mortality, and hs-CRP was one of the inde-
pendent predictors of all-cause mortality in DCM patients.
As for big-ET, although many studies showed that big-
ET levels were elevated and were prognostic markers of
survival in patients with chronic heart failure [21-24], in
the present study, big-ET was not one of the indepen-
dent predictors of all-cause mortality in DCM patients.
The present study has several limitations; as with many
studies of chronic disease, there may be variation in the
length of the preclinical phase that influences the relation-
ships between the three biomarkers of NT pro-BNP, hs-CRP,
big-ET and death. The cohort in the present study included
only patients with DCM who required hospitalization, and
thus, the data described herein cannot be extrapolated to the
entire DCM population. In addition, the medicines on ad-
mission should add some influence to the Cox multivariate
analysis as without long-term medicine data. Finally, we
measured the three biomarkers just at admission without
the discharge values or more in the present study.Conclusion
In conclusion, in the present study, our findings suggest
that hs-CRP > 3.90 mg/L and NT pro-BNP > 2247 pmol/L
were associated with all-cause mortality in DCM patients
and were some of the independent predictors of all-cause
mortality after adjusting for the classic risk factors of HF in
patients with DCM. However, big-ET > 0.95 pmol/L was
not associated with higher all-cause mortality.
Table 2 Patient characteristics categorized by plasma hs-CRP or big-ET levels1
All of the patients (n = 622) hs-CRP < 3.91 mg/L (n = 375) hs-CRP > 3.91 mg/L
(n = 247)
P value Big ET < 0.95 pmol/mL
(n = 335)
Big ET > 0.95 pmol/mL
(n = 287)
P value
Age (years) 50.1 ± 14.3 50.1 ± 14.1 52.5 ± 14.2 0.051 51.2 ± 14.1 51.0 ± 14.5 0.846
Female sex, n (%) 160 (25.7) 102 (27.2) 58 (23.5) 0.299 88 (26.3) 72 (25.1) 0.737
History
Course 3 (0.5-7) 2 (0.35-7) 3 (0.6-6) 0.170 3 (0.5-6) 2.5 (0.35-7) 0.628
Diabetes mellitus 92 (14.8) 57 (15.2) 35 (14.2) 0.723 45 (13.4) 47 (16.4) 0.303
Atrial fibrillation, n (%) 142 (22.8) 79 (21.1) 63 (25.5) 0.197 62 (18.5) 80 (27.9) 0.006
Smoker, n (%)2 294 (47.3) 172 (45.9) 122 (49.4) 0.396 159 (47.5) 135 (47.0) 0.953
Drinker, n (%)2 190 (30.5) 119 (31.7) 71 (28.7) 0.422 103 (30.7) 87 (30.3) 0.933
NYHA class III and IV, n (%)3 468 (75.2) 250 (66.7) 218 (88.3) <0.001 217 (64.8) 251 (87.5) <0.001
Admission vital signs
SBP (mm Hg)3 113.2 ± 17.7 115.0 ± 31.1 118.7 ± 29.4 0.002 116.1 ± 17.6 109.7 ± 17.1 <0.001
DBP (mm Hg)3 72.2 ± 12.6 73.4 ± 12.1 70.4 ± 13.1 0.004 72.9 ± 12.2 71.4 ± 13.1 0.135
Heart rate, beat/min 80.5 ± 17.2 78.3 ± 16.2 83.9 ± 18.1 <0.001 78.7 ± 16.6 71.4 ± 13.1 0.004
Laboratory values at admission4
Glucose (mmol/L) 5.52 ± 1.66 5.44 ± 1.39 5.64 ± 1.99 0.154 5.57 ± 1.65 5.46 ± 1.66 0.425
TG (mmol/L)3 1.58 ± 0.90 1.68 ± 1.00 1.41 ± 0.69 <0.001 1.74 ± 0.94 1.38 ± 0.81 <0.001
TC (mmol/L)3 4.57 ± 1.11 4.68 ± 1.02 4.40 ± 1.22 0.004 4.84 ± 1.06 4.25 ± 1.09 <0.001
Creatinine (μmol/L) 92.3 ± 34.7 88.2 ± 29.9 98.4 ± 40.3 0.001 89.0 ± 28.5 96.1 ± 40.6 0.011
BUN (μmol/L)3 8.02 ± 4.09 7.89 ± 4.21 8.22 ± 3.89 0.328 7.96 ± 4.10 8.10 ± 4.07 0.666
NT Pro-BNP (pmol/mL)3 1652.85 (837.375-2907.2) 1367 (736.75-2259.4) 2281.5 (1218.1-3589.4) <0.001 1089 (714.675-1949.1) 2529.05 (1439.1-3608.475) <0.001
Electrocardiogram data2
QRS duration (ms) 119.2 ± 30.4 119.6 ± 31.1 118.7 ± 29.4 0.720 119.4 ± 30.2 119.0 ± 30.7 0.883
QT (ms) 407.7 ± 51.0 411.9 ± 50.5 401.2 ± 51.1 0.011 413.9 ± 49.6 400.4 ± 51.7 0.001
Echocardiography data4
LV (mm)3 68.3 ± 9.5 67.8 ± 9.5 69.3 ± 9.4 0.055 67.3 ± 8.9 69.5 ± 10.1 0.005
LVEF (mm)3 31.2 ± 8.5 32.2 ± 8.7 29.8 ± 7.9 0.001 33.0 ± 8.5 29.2 ± 7.9 <0.001
RV (mm) 24.2 ± 5.5 23.3 ± 5.0 25.5 ± 5.9 <0.001 22.6 ± 4.2 26.0 ± 6.1 <0.001


















Table 2 Patient characteristics categorized by plasma hs-CRP or big-ET levels1 (Continued)
Medicine at admission2
Diuretics, n (%) 589 (94.7) 352 (93.9) 237 (96.0) 0.080 314 (93.7) 275 (95.8) 0.048
ACEI/ARB, n (%)3 522 (83.9) 330 (88.0) 192 (77.7) 0.003 289 (86.3) 233 (81.2) 0.126
Beta-blockers, n (%) 564 (90.7) 349 (93.1) 215 (87.0) 0.038 306 (91.3) 258 (89.9) 0.857
Digoxin, n (%) 497 (79.9) 287 (76.5) 210 (85.0) 0.004 259 (77.3) 238 (82.9) 0.038
Aspirin/anticoagulation n (%) 393 (63.2) 237 (63.2) 156 (63.2) 0.868 211 (63.0) 182 (63.4) 0.725
Spironolactone, n (%) 572 (92.0) 347 (92.5) 225 (91.1) 0.837 306 (91.3) 266 (92.7) 0.193
Note:
1Data are expressed as the mean ± SD, median (interquartile range) or percentage; P values are from an independent-samples t-test.
2Smoker was defined using standard questions about current smoking and lifetime smoking at least 100 cigarettes; drinkers who reported drinking 1 drink a day on average on days that they consumed alcohol
during the previous year.
3Abbreviations: NYHA New York Heart Association, SBP systolic blood pressure, DBP diastolic blood pressure, BUN blood urea nitrogen, TG triglycerides, TC total cholesterol, NT pro-BNP N-terminal fragment
pro-brain natriuretic peptide, LV left ventricle, RV right ventricle, LA left atrium, LVEF left ventricular ejection fraction, ACEI angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker.
4Ten patients lacked echocardiography data, 9 patients lacked electrocardiogram data, 4 patient lacked fasting blood glucose, 62 patients lacked NT-pro-BNP levels, 1 patient lacked creatinine, 2 patients lacked BUN
levels, 5 patients lacked triglyceride, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol, 62 patients lacked NT pro-BNP levels, and 6 patients lacked medicines at admission.
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